OK-432 therapy for lymphangiomas.
OBJECTIVE
To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.


METHODS
Nonrandomized trial; follow-up, 4 to 29 months.


METHODS
Academic tertiary referral medical center.


METHODS
Six children with presumed lymphangiomas; age range at initial treatment, 1 month to 7 years 10 months.


METHODS
Fluoroscopically guided cyst aspiration, cystography, and injection of OK-432.


METHODS
Clinical and radiographic comparisons before and after therapy.


RESULTS
Complete response in 2 macrocystic lymphangiomas; no response in 3 microcystic lymphangiomas; and no response in 1 venous malformation.


CONCLUSIONS
OK-432 sclerotherapy may be effective treatment for macrocystic lymphangiomas.
Department of Otolaryngology, University of Iowa, Iowa City, USA.
R J
RJ
Smith
D K
DK
Burke
Y
Y
Sato
R I
RI
Poust
K
K
Kimura
N M
NM
Bauman
D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D007223:Infant; D018191:Lymphangioma, Cystic / Q000000981:diagnostic imaging / Q000628:therapy*; D008297:Male; D010844:Picibanil / Q000627:therapeutic use*; D011859:Radiography; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000379:methods
D012597:Sclerosing Solutions; D010844:Picibanil